« Return to News | Ethics/Regulatory

FDA’s CDRH sets goals for personalized medicine

Tuesday, January 24, 2012 02:51 PM

The FDA's Center for Devices and Radiological Health has set personalized medicine as one of its priorities for the current year, aiming for draft guidance on co-development of drugs and diagnostics by year's end.

In CDRH’s 2012 Strategic Priorities document, priority four is to proactively facilitate innovation and address unmet public health needs, anticipating emerging technological trends and public health challenges and partnering with federal and external stakeholders to facilitate the development of innovative, safe and effective medical devices and advance regulatory science.

Within this priority, one of CDRH’s strategies is to further develop a personalized medicine program. It will work collaboratively with federal government partners and external constituencies to assure the appropriate regulatory oversight of therapeutics and diagnostics when their safety and effectiveness are intimately tied to one another.

The center’s goals include continuing to develop policies and procedures to assure that safe and effective diagnostic products are either innovative themselves or provide innovative uses reach the public. By June 30, 2012, CDRH plans to clear final guidance on Companion Diagnostics. By Dec. 31, 2012, CDRH plans to clear draft guidance on co-development of drugs or biologics and devices.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.